Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma
Open Access
- 22 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 28 (1), 1-14
- https://doi.org/10.1186/s12929-021-00727-5
Abstract
Due to the difficulties in early diagnosing and treating hepatocellular carcinoma (HCC), prognoses for patients remained poor in the past decade. In this study, we established a screening model to discover novel prognostic biomarkers in HCC patients. Candidate biomarkers were screened by liquid chromatography with tandem mass spectrometry (LC-MS/MS) analyses of five HCC normal (N)/tumor (T) paired tissues and preliminarily verified them through several in silico database analyses. Expression levels and functional roles of candidate biomarkers were respectively evaluated by immunohistochemical staining in N/T paired tissue (n = 120) and MTS, colony formation, and transwell migration/invasion assays in HCC cell lines. Associations of clinicopathological features and prognoses with candidate biomarkers in HCC patients were analyzed from GEO and TCGA datasets and our recruited cohort. We found that the transmembrane P24 trafficking protein 9 (TMED9) protein was elevated in HCC tissues according to a global proteomic analysis. Higher messenger (m)RNA and protein levels of TMED9 were observed in HCC tissues compared to normal liver tissues or pre-neoplastic lesions. The TMED9 mRNA expression level was significantly associated with an advanced stage and a poor prognosis of overall survival (OS, p = 0.00084) in HCC patients. Moreover, the TMED9 protein expression level was positively correlated with vascular invasion (p = 0.026), OS (p = 0.044), and disease-free survival (p = 0.015) in our recruited Taiwanese cohort. In vitro, manipulation of TMED9 expression in HCC cells significantly affected cell migratory, invasive, proliferative, and colony-forming abilities. Ours is the first work to identify an oncogenic role of TMED9 in HCC cells and may provide insights into the application of TMED9 as a novel predictor of clinical outcomes and a potential therapeutic target in patients with HCC.Keywords
This publication has 51 references indexed in Scilit:
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival AnalysisPLOS ONE, 2013
- Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC‐MS/MSElectrophoresis, 2013
- A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasmaJournal of Proteomics, 2012
- High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate CancerPLOS ONE, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- The trafficking protein Tmed2/p24β1 is required for morphogenesis of the mouse embryo and placentaDevelopmental Biology, 2010
- The p24 family and selective transport processes at the ER—Golgi interfaceBiology of the Cell, 2009
- Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinomaBMC Cancer, 2009
- Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resectionLaboratory Investigation, 2008
- Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinomaJournal of Hepatology, 1994